Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone palmitate versus oral antipsychotic monotherapy for relapse prevention in recently diagnosed schizophrenia
NL-OMON32671Phase 3Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2009
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paliperidone palmitate in schizophrenia (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Time to relapse. Planned start Dec 2009; status: withdrawn.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NL-OMON32671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32671.